Immunome, Inc.
NASDAQ:IMNMBiotechnology
-$0.42 today
- Market cap
- $2.03B
- Beta
- 2.07
- P/E (TTM)
- -9.1
- EPS (TTM)
- -$1.99
Volume 1.03M
Average 1.23M
IMNM EBITDA Margin
EBITDA as a percentage of revenue.
Immunome, Inc.NASDAQ: IMNM
EBITDA Margin · Q3 FY2026 · quarter ended Sep 2026
EBITDA Margin not reported for Q3 FY2026
Context
- EBITDA Margin widened in 0 of the last 2 fiscal years.
- FY2025 was the lowest level in the 3 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 7 analysts of -153482.6% for the fiscal year ending Dec 2026, down from -3017.4% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterSep 2026
- —— QoQ
- Last fiscal yearDec 2025
- -3017.4%-1343.3 pp YoY
- LTMSep 2026
- —— YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | — | — | — |
| 1 year | -1343.3 pp | -150465.2 pp | -149121.9 pp |
| 3 years | — | +2907.1 pp | — |
| 5 years | +3047.6 pp | — | |
| 10 years | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -3017.4%
- Year-over-year change
- -1343.3pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -3017.4% | -1343.3pp |
| FY2024 | 2024-12-31 | -1674.1% | -1474.3pp |
| FY2023 | 2023-12-31 | -199.7% | — |
| FY2022 | 2022-12-31 | — | — |
| FY2021 | 2021-12-31 | — | — |
EBITDA Margin vs competitors
How IMNM compares with its peers on the latest reported figures
- IMNM's FY2025 EBITDA Margin of -3017.4% is the 6th highest of the 7 companies compared; the peer median is -219.8%.
- Its year-over-year change of -1343.3 pp is the 6th highest of 7, against a peer median of +0.2 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 1.6% | +1.6 pp | +26.7 pp | |
| LTM Mar 2026 | -32.2% | -1.2 pp | +32.0 pp | |
| LTM Mar 2026 | -106.5% | +169.1 pp | +12.9 pp | |
| LTM Mar 2026 | -333.1% | +482.9 pp | +448.9 pp | |
| LTM Mar 2026 | -542.7% | -539.6 pp | -412.4 pp | |
| FY2025 | -3017.4% | -1343.3 pp | — | |
| LTM Sep 2026 | -272652.7% | -264146.9 pp | -12607.1 pp | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding IMNM) | -219.8% | +0.2 pp | +19.8 pp | |
Competitors are the stored peer set for IMNM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 14.02M | 9.04M | 6.94M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 2.96M |
| Gross Profit | 0 | 0 | 14.02M | 9.04M | 3.99M |
| Gross Margin | — | — | 100.0% | 100.0% | 57.4% |
| Research & Development | 14.11M | 23.27M | 23.09M | 129.54M | 174.33M |
| Selling, General & Admin | 11.09M | 13.63M | 19.66M | 32.96M | 43.77M |
| Operating Expenses | 25.2M | 36.9M | 123.55M | 314.84M | 218.1M |
| Depreciation & Amortization | 755K | 631K | 728K | 2.1M | 2.96M |
| EBITDA | (23.95M) | (36.26M) | (28M) | (151.35M) | (209.44M) |
| EBITDA Margin | — | — | -199.7% | -1674.1% | -3017.4% |
| Operating Income | (25.2M) | (36.9M) | (109.53M) | (305.8M) | (214.11M) |
| Operating Margin | — | — | -781.4% | -3382.4% | -3084.8% |
| Interest Income | 10K | 5K | 2.72M | 12.84M | 11.72M |
| Interest Expense | 10K | 5K | 0 | 0 | 0 |
| Other Income / Expenses | 493K | 5K | 2.72M | 12.84M | 1.72M |
| Income Before Tax | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Pre-Tax Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (24.71M) | (36.9M) | (106.81M) | (292.96M) | (212.39M) |
| Net Margin | — | — | -761.9% | -3240.4% | -3060.0% |
| EPS (Basic) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| EPS (Diluted) | (2.14) | (3.09) | (5.38) | (5.00) | (2.43) |
| Weighted Avg Shares | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
| Weighted Avg Shares (Diluted) | 11.54M | 12.13M | 19.84M | 58.64M | 87.35M |
Immunome, Inc.
NASDAQ:IMNM
Intrinsic Alpha fair value
Locked
Current Price
$17.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.